Hemab
Uya Chuluunbaatar, PhD, is a Partner at Avoro Ventures. Prior to joining Avoro Ventures, Uya was a Principal at Amzak Health where she led private and public biotech investments. Prior to Amzak, Uya was a biotech equity research analyst at Goldman Sachs, covering large and mid-cap companies. Uya completed her Ph.D in Microbiology at New York University School of Medicine and holds a B.S. in Biochemistry from Cornell University, United States.
This person is not in the org chart
This person is not in any teams
This person is not in any offices
Hemab
Hemab Therapeutics ApS is an emerging biotech company supported by Novo Holdings A/S with the aim of developing novel treatments for rare and underserved bleeding disorders. Based in Copenhagen, the company is led by a team of drug developers and scientists with deep expertise in haemophilia. Hemab has exclusive licences to state-of-the-art antibody technologies from both Novo Nordisk A/S and Genmab A/S.